Anthrax vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Anthrax vaccine
Accession Number
DB11003  (DB06648)
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Description

Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium [FDA Label].

Synonyms
  • Anthrax vaccine adsorbed
  • Bacillus anthracis inactivated antigen
  • Bacillus anthracis strain V770-NP1-R antigen
  • Bacillus anthracis strain V770-NP1-R antigens
  • Bacillus anthracis strain V770-NP1-R filtrate (attenuated) antigen
  • Bacillus anthracis strain V770-NP1-R filtrate antigen
External IDs
RPA102
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BioThraxSuspension50 mcgIntramuscular; SubcutaneousEmergent Biodefense Operations Lansing LlcNot applicableNot applicableCanada
BioThraxInjection, suspension100 ug/1mLIntramuscular; SubcutaneousEmergent BioDefense Operations Lansing, LLC1970-11-04Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
873OI62848
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Associated Therapies
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe risk or severity of infection can be increased when Anthrax vaccine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Anthrax vaccine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbacavirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Anthrax vaccine is combined with Abatacept.
AbetimusThe risk or severity of infection can be increased when Anthrax vaccine is combined with Abetimus.
ActeosideThe risk or severity of infection can be increased when Anthrax vaccine is combined with Acteoside.
AcyclovirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Acyclovir.
AdafosbuvirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Adafosbuvir.
AdalimumabThe risk or severity of infection can be increased when Anthrax vaccine is combined with Adalimumab.
AdefovirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Adefovir.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911075
Wikipedia
Anthrax_vaccine
FDA label
Download (363 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionAnthrax1
1CompletedPreventionAnthrax Infection1
1CompletedPreventionBacillus Anthracis (Anthrax) Infection1
1CompletedPreventionPrevention of Anthrax Infection1
1CompletedTreatmentAnthrax1
1Not Yet RecruitingPreventionAnthrax1
1RecruitingPreventionHealthy Volunteers1
2Active Not RecruitingPreventionAnthrax1
2CompletedPreventionAnthrax2
2CompletedTreatmentAnthrax1
2TerminatedPreventionBacillus Anthracis (Anthrax)1
3Active Not RecruitingPreventionAnthrax1
3CompletedTreatmentAnthrax1
4CompletedPreventionBacillus Anthracis (Anthrax)1
4CompletedPreventionHealthy Volunteers1
Not AvailableActive Not RecruitingNot AvailableComplications, Pregnancy / Congenital Abnormalities / Pregnancy Outcomes1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular; Subcutaneous100 ug/1mL
SuspensionIntramuscular; Subcutaneous50 mcg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:05 / Updated on December 02, 2019 08:55